AIM ImmunoTech Statistics
Total Valuation
AIM ImmunoTech has a market cap or net worth of $7.50 million. The enterprise value is $9.47 million.
Important Dates
The next estimated earnings date is Friday, November 14, 2025, before market open.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AIM ImmunoTech has 2.71 million shares outstanding. The number of shares has increased by 34.14% in one year.
| Current Share Class | 2.71M |
| Shares Outstanding | 2.71M |
| Shares Change (YoY) | +34.14% |
| Shares Change (QoQ) | +7.96% |
| Owned by Insiders (%) | 4.39% |
| Owned by Institutions (%) | 2.59% |
| Float | 2.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 62.01 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 78.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.10
| Current Ratio | 0.10 |
| Quick Ratio | 0.08 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -27.36 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -104.62% |
| Return on Invested Capital (ROIC) | -362.96% |
| Return on Capital Employed (ROCE) | 265.15% |
| Revenue Per Employee | $5,261 |
| Profits Per Employee | -$702,870 |
| Employee Count | 23 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.43 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 2.60 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 49.93 |
| Average Volume (20 Days) | 75,947 |
Short Selling Information
The latest short interest is 44,801, so 1.65% of the outstanding shares have been sold short.
| Short Interest | 44,801 |
| Short Previous Month | 8,148 |
| Short % of Shares Out | 1.65% |
| Short % of Float | 1.73% |
| Short Ratio (days to cover) | 0.29 |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of $121,000 and -$16.17 million in losses. Loss per share was -$24.12.
| Revenue | 121,000 |
| Gross Profit | 86,000 |
| Operating Income | -16.61M |
| Pretax Income | -16.17M |
| Net Income | -16.17M |
| EBITDA | -16.37M |
| EBIT | -16.61M |
| Loss Per Share | -$24.12 |
Full Income Statement Balance Sheet
The company has $835,000 in cash and $2.81 million in debt, giving a net cash position of -$1.97 million or -$0.73 per share.
| Cash & Cash Equivalents | 835,000 |
| Total Debt | 2.81M |
| Net Cash | -1.97M |
| Net Cash Per Share | -$0.73 |
| Equity (Book Value) | -6.55M |
| Book Value Per Share | -8.57 |
| Working Capital | -9.37M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$10.96 million and capital expenditures -$18,000, giving a free cash flow of -$10.98 million.
| Operating Cash Flow | -10.96M |
| Capital Expenditures | -18,000 |
| Free Cash Flow | -10.98M |
| FCF Per Share | -$4.05 |
Full Cash Flow Statement Margins
| Gross Margin | 71.07% |
| Operating Margin | -13,726.45% |
| Pretax Margin | -13,360.33% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AIM ImmunoTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -34.14% |
| Shareholder Yield | -34.14% |
| Earnings Yield | -215.46% |
| FCF Yield | -146.27% |
Analyst Forecast
The average price target for AIM ImmunoTech is $12.50, which is 378.93% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.50 |
| Price Target Difference | 378.93% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 270.24% |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 12, 2025. It was a reverse split with a ratio of 1:100.
| Last Split Date | Jun 12, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
AIM ImmunoTech has an Altman Z-Score of -162.21 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -162.21 |
| Piotroski F-Score | 2 |